PHREESIA Earnings Results: $PHR Reports Quarterly Earnings

Phreesia ($PHR) reported a quarterly earnings per share of -$0.07, surpassing estimates of -$0.12, while revenue of $115.94 million missed estimates by approximately $200,000. Over the past six months, company insiders have predominantly sold shares, and recent hedge fund activity shows mixed sentiment with some firms significantly increasing their positions (e.g., UBS AM and AMERICAN CENTURY COMPANIES INC) while others reduced theirs (e.g., BROWN ADVISORY INC); currently, two analysts have issued buy ratings with a median price target of $31.

Analysis

Phreesia ($PHR) recently reported mixed quarterly financial results, with earnings per share of -$0.07 beating consensus estimates of -$0.12 by $0.05, but revenue of $115.94 million narrowly missing estimates of $116.14 million by $203,940. A significant point of concern is the extensive insider selling activity over the past six months, where 97 transactions were sales and none were purchases. This includes substantial divestments by key executives: the Chief Operating Officer sold 95,488 shares for approximately $2.56 million, the Chief Executive Officer sold 71,563 shares for roughly $1.90 million, and the Chief Financial Officer sold 64,922 shares for an estimated $1.85 million, among other senior leaders. Institutional ownership reveals a divided sentiment; while 120 institutions added PHR to their portfolios in the most recent quarter (Q1 2025 for most reported moves), with notable increases from UBS AM (+1.38 million shares) and American Century Companies Inc. (+0.96 million shares), 98 institutions reduced their positions. Significant reductions included Brown Advisory Inc. divesting 1.82 million shares in Q1 2025 and TimesSquare Capital Management liquidating its entire position of 0.87 million shares in Q4 2024. Despite these headwinds, Wall Street analyst sentiment appears positive, with two firms, Citigroup and KeyBanc, issuing "Buy" or "Overweight" ratings in early January 2025 (as per article dates). Two analysts have provided price targets in the last six months, with a median target of $31.0, supported by individual targets of $30.0 and $32.0.

Key Decisions for Investors

• Investors should carefully weigh Phreesia's earnings per share beat and positive analyst price targets against the slight revenue miss and the pronounced, widespread insider selling across senior management.
• The significant volume of insider sales, totaling 97 sell transactions with no buys in the last six months, warrants heightened scrutiny and could signal internal concerns regarding the company's valuation or outlook, despite external analyst optimism.
• Given the mixed institutional sentiment, with major funds both increasing and decreasing stakes, a cautious approach is advisable; closely monitor future revenue performance, any shifts in insider transaction patterns, and further institutional flow data before committing new capital or adjusting existing positions.